Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1391
Shown on this page
12
Current sort
Recently updated
Campus scope
UCSF, San Francisco, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCSF, San Francisco, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 217–228 of 1,391 matching trials with a site at UCSF, San Francisco, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome

NCT05035030
Site status not listed — check the official record
View directory record Official record
Conditions
Alagille Syndrome
Interventions
Odevixibat
Drug
Lead sponsor
Albireo, an Ipsen Company
Industry
Eligibility
Not listed
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
18
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 1:24 AM EDT
Not yet recruiting Not applicable Interventional

The Application of Lifestyle Enhancing Validated Integrative Therapies for Everyday Pain in Cirrhosis

NCT07792850
Site status not listed — check the official record
View directory record Official record
Conditions
Cirrhoses, Liver
Interventions
High-touch self-management program, Low-touch self-management program
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 1:24 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Gauging Outcomes of Total Milk Ingestion on Lipid and gControl

NCT07087184
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Diseases, Cardiovascular Disease
Interventions
Whole Milk-Skim Milk, Skim Milk-Whole Milk
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 1:24 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

NCT02595424
Site status not listed — check the official record
View directory record Official record
Conditions
Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions
Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
673
States / cities
Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 1:24 AM EDT
Recruiting Phase 3 Interventional

CAR-T Long Term Follow Up (LTFU) Study

NCT02445222
Status at this site: Recruiting
View directory record Official record
Conditions
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Interventions
Previously treated CAR-T patients
Genetic
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 100 Years
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2039
U.S. locations
42
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 1:24 AM EDT
Recruiting Phase 3 Interventional

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

NCT07491445
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Interventions
daraxonrasib, gemcitabine, nab-paclitaxel
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 1:24 AM EDT
Recruiting Phase 1 Interventional

Imaging Study of [89Zr]DFO-YS5 for Cancer Detection

NCT07664397
Status at this site: Recruiting
View directory record Official record
Conditions
Bladder Cancer, Nerve Sheath Tumor, Nerve Sheath Tumors, Solid Tumor Malignancies, Solid Tumor Cancer, Solid Tumor Neoplasms, Advanced Solid Tumor, Bladder Neoplasm, Nerve Sheath Neoplasms, Nerve Sheath Tumor, Nos, Solid Tumor, Adult, Solid Carcinoma
Interventions
[89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT)
Drug · Procedure
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 1:24 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

NCT03970447
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 1:24 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

NCT01169337
Site status not listed — check the official record
View directory record Official record
Conditions
Light Chain Deposition Disease, Smoldering Multiple Myeloma
Interventions
Clinical Observation, Lenalidomide, Quality-of-Life Assessment
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
601
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 390 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 1:24 AM EDT
Recruiting Phase 3 Interventional

Parasitic Ulcer Treatment Trial

NCT06213649
Status at this site: Recruiting
View directory record Official record
Conditions
Acanthamoeba Keratitis
Interventions
Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical placebo
Drug · Other
Lead sponsor
Jeremy Keenan, MD, MPH
Other
Eligibility
8 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 1:24 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

NCT06285643
Site status not listed — check the official record
View directory record Official record
Conditions
Parkinson Disease
Interventions
AAV2-GDNF gene therapy, control surgery
Drug · Procedure
Lead sponsor
AskBio Inc
Industry
Eligibility
45 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 1:24 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

NCT03914625
Site status not listed — check the official record
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
Interventions
Asparaginase Erwinia chrysanthemi, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Mercaptopurine Oral Suspension, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Biological · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
365 Days to 31 Years
Enrollment
6,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
201
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 1:24 AM EDT

About this UCSF institution page

What this page lists
ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of California, San Francisco at any site, browse by condition, or browse by U.S. city.